Acute Vulvovaginal Candidiasis Market

Report ID : 1232 | Published : 2022-06-02 | Pages: | Format: PDF/EXCEL

The Global Acute Vulvovaginal Candidiasis Treatment Market is estimated to reach over USD 485.54 million by 2030, exhibiting a CAGR of 4.80% during the forecast period.

The acute vulvovaginal candidiasis market includes the development of several treatments and medications for the treatment of acute vulvovaginal candidiasis. The candida albicans fungus causes acute vulvovaginal candidiasis (VVC), which is also known as vaginal thrush. The illness is caused by a fungal overgrowth, which manifests as abnormal vaginal discharge, acute discomfort during intercourse, and vaginal itching. Approximately 75 % of women are projected to be affected by the VVC at some point in their lives. Although the majority of VVC cases are small, the infection can develop seriously in some women, resulting in swelling, cracks in the vaginal wall, and redness.

Furthermore, the demand for acute vulvovaginal candidiasis therapy is increasing in lockstep with the global disease burden, indicating a growing desire for better treatment options and a rise in the number of hospital-acquired infections. The development of new antifungal drugs, an increase in healthcare spending, and the growth of healthcare infrastructure are also driving the global acute vulvovaginal candidiasis treatment market. Furthermore, market participants compete for clearance to manufacture their products by submitting new drug applications (NDAs) to regulatory organizations. As a result of this factor, the global acute vulvovaginal candidiasis market is expected to grow.

However, the global acute vulvovaginal candidiasis therapy market is predicted to be hampered by the COVID-19 pandemic over the forecast period. According to the Indian Journal of Medical Sciences, on June 6, 2020, the COVID-19 pandemic has impeded the conduct of clinical trials due to a lack of trial site employees, travel restrictions, experimental product supply, and other problems. The development of new therapeutics for acute vulvovaginal candidiasis is hampered by these roadblocks. Infection with Candida albicans is becoming increasingly common among patients in intensive care units. Furthermore, prominent firms have suspended operations in various places due to the lockdown and social distancing practices.

Market Segmentation:

The Acute Vulvovaginal Candidiasis Treatment Market is segmented based on Drug Types, Route of Administration, and Distribution Channels. Based on Drug Types, the market is bifurcated as Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, and Other Drug Types. Based on Route of Administration, the market is categorized into Oral, Intravenous, and Topical. Based on Distribution Channels, the market is segmented as Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Based on Drug Types, the Clotrimazole segment is accounted as a major contributor to the Acute Vulvovaginal Candidiasis Treatment Market.

Clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others are the medication types that make up the global acute vulvovaginal candidiasis therapy market. Due to its high efficiency and widespread use in the treatment of acute vulvovaginal candidiasis, the clotrimazole segment is likely to dominate the global market throughout the projection period.

The hospital Pharmacies segment witnessed growth at a rapid rate.

The global acute vulvovaginal candidiasis treatment market can be divided into hospital pharmacies, retail pharmacies, internet pharmacies, and other distribution channels. As a result of the huge number of patients treated in hospitals, the hospital pharmacies segment is anticipated to hold a significant portion of the global acute vulvovaginal candidiasis treatment market by 2031.

In the region, the Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market holds a significant revenue share.

The Asia Pacific acute vulvovaginal candidiasis market is likely to grow significantly over the forecast period. The global acute vulvovaginal candidiasis market is being boosted by raising awareness of this ailment among rural women, as well as Indian government programmes such as 'Swachhta, Swasthya, and Suvidha' to promote the cleanliness of poor women. Furthermore, developing economies such as China and Japan are expected to contribute to market expansion in the Asia Pacific as a result of improved healthcare infrastructure, an increase in the number of insurance payers, economic growth, the development of the private healthcare sector, and an increase in education and awareness. However, North America is also expected to rise fast over the forecast period in the worldwide acute vulvovaginal candidiasis market.

Competitive Landscape

In the global acute vulvovaginal candidiasis treatment market over the forecast period, new drug development is expected to drive growth in the global acute vulvovaginal candidiasis treatment market. To grow their product portfolio, major players in the global acute vulvovaginal candidiasis treatment market are focusing on getting new medications approved and launched. Cadila Pharmaceuticals, for example, released Fenticonazole Nitrate Vaginal Capsules for the treatment of acute vulvovaginal candidiasis. Furthermore, Scynexis, for example, submitted a new medication application to the US Food and Drug Administration for the treatment of acute vulvovaginal candidiasis using oral ibrexafungerp. Some of the major market players are, Mycovia Pharmaceuticals, Inc., Scynexis, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Padagis LLC, ProFem GmbH, Amplyx Pharmaceuticals Inc., MethylGene Inc., Ferrer Internacional S.A., Pfizer, Inc., and Other Prominent Players

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Acute Vulvovaginal Candidiasis Treatment Market Snapshot

Chapter 4. Global Acute Vulvovaginal Candidiasis Treatment Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Types Estimates & Trend Analysis

5.1. By Drug Types & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Drug Types:

5.2.1. Clotrimazole

5.2.2. Nystatin

5.2.3. Fluconazole

5.2.4. Ketoconazole

5.2.5. Terbinafine

5.2.6. Terconazole

5.2.7. Other Drug Types

Chapter 6. Market Segmentation 2: By Route of Administration Estimates & Trend Analysis

6.1. By Route of Administration & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Route of Administration:

6.2.1. On-Cloud

6.2.2. Web-Based

6.2.3. On-Premises

Chapter 7. Market Segmentation 3: By Distribution Channels Estimates & Trend Analysis

7.1. By Distribution Channels & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channels:

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

Chapter 8. Acute Vulvovaginal Candidiasis Treatment Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts By Drug Types, 2019-2030

8.1.2. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

8.1.3. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2019-2030

8.1.4. North America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

8.2. Europe

8.2.1. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2019-2030

8.2.2. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2019-2030

8.2.3. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2019-2030

8.2.4. Europe Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2019-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2019-2030

8.3.2. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2019-2030

8.3.3. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2019-2030

8.3.4. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2019-2030

8.4. Latin America

8.4.1. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2019-2030

8.4.2. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2019-2030

8.4.3. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2019-2030

8.4.4. Latin America Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2019-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Drug Types, 2019-2030

8.5.2. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) By Route of Administration, 2019-2030

8.5.3. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2019-2030

8.5.4. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market revenue (US$ Million) by country, 2019-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Mycovia Pharmaceuticals, Inc.

9.2.2. Scynexis, Inc.

9.2.3. Basilea Pharmaceutica Ltd.

9.2.4. Astellas Pharma Inc.

9.2.5. Grupo Ferrer Internacional, S.A.

9.2.6. Pacgen Life Science Corporation

9.2.7. NovaDigm Therapeutics, Inc.

9.2.8. Cidara Therapeutics, Inc.

9.2.9. Padagis LLC

9.2.10. ProFem GmbH

9.2.11. Amplyx Pharmaceuticals Inc.

9.2.12. MethylGene Inc.

9.2.13. Ferrer Internacional S.A.

9.2.14. Pfizer, Inc.

9.2.15. Other Prominent Players

Segmentation of Acute Vulvovaginal Candidiasis Treatment Market-

By Drug Type-

  • Clotrimazole
  • Nystatin
  • Fluconazole
  • Ketoconazole
  • Terbinafine
  • Terconazole
  • Other Drug Types

By Route of Administration -

  • Oral
  • Intravenous
  • Topical

By Distribution Channels -

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients